Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor  tyrosine kinase inhibitor.
The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue, and cough.
Osimertinib was approved for medical use in the United States in November 2015, and in the European Union in February 2016.